Checkpoint Therapeutics (NASDAQ:CKPT) Shares Down 1%

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) shares fell 1% on Tuesday . The company traded as low as $1.42 and last traded at $1.44. 352,028 shares traded hands during trading, a decline of 35% from the average session volume of 541,909 shares. The stock had previously closed at $1.45.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $34.00 price target on shares of Checkpoint Therapeutics in a report on Friday, March 22nd. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Checkpoint Therapeutics currently has an average rating of “Buy” and a consensus target price of $22.60.

Checkpoint Therapeutics Trading Down 1.0 %

The business’s 50-day moving average price is $1.94 and its 200-day moving average price is $2.06. The stock has a market cap of $51.22 million, a PE ratio of -0.43 and a beta of 0.99.

Checkpoint Therapeutics (NASDAQ:CKPT) last issued its quarterly earnings data on Friday, March 22nd. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.36). The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.09 million. As a group, analysts predict that Checkpoint Therapeutics, Inc. will post -1.34 earnings per share for the current year.

Institutional Trading of Checkpoint Therapeutics

Several large investors have recently bought and sold shares of the stock. Armistice Capital LLC grew its position in Checkpoint Therapeutics by 17.5% during the 4th quarter. Armistice Capital LLC now owns 2,426,000 shares of the company’s stock worth $5,556,000 after purchasing an additional 362,000 shares during the last quarter. Sabby Management LLC purchased a new stake in Checkpoint Therapeutics during the 3rd quarter worth approximately $349,000. B. Riley Wealth Advisors Inc. grew its position in Checkpoint Therapeutics by 232.3% during the 4th quarter. B. Riley Wealth Advisors Inc. now owns 163,350 shares of the company’s stock worth $374,000 after purchasing an additional 114,200 shares during the last quarter. PVG Asset Management Corp grew its position in Checkpoint Therapeutics by 81.9% during the 3rd quarter. PVG Asset Management Corp now owns 111,025 shares of the company’s stock worth $189,000 after purchasing an additional 50,000 shares during the last quarter. Finally, Legacy Wealth Asset Management LLC grew its position in Checkpoint Therapeutics by 104.8% during the 3rd quarter. Legacy Wealth Asset Management LLC now owns 85,000 shares of the company’s stock worth $144,000 after purchasing an additional 43,500 shares during the last quarter. Hedge funds and other institutional investors own 22.00% of the company’s stock.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.